United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

UTHR currently has a forward P/E ratio of 12.63, while ZTS has a forward P/E of 27.56. We also note that UTHR has a PEG ratio of 0.92. This metric is used similarly to the famous P/E ratio, but the ...

A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $15.77 billion market cap company with an "Excellent" financial health rating according to InvestingPro, executed a ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The final step today is to look at a stock that meets our ESP qualifications. United Therapeutics (UTHR) earns a #2 (Buy) 14 days from its next quarterly earnings release on February 19 ...

If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.